Cannabidiol as a potential treatment for psychosis.
Subject: Schizophrenia - PUBLISHED VIA European Neuropsychopharmacology
Author(s):
Schubart CD, Sommer IE, Fusar-Poli P, de Witte L, Kahn RS, Boks MP
View Source >>
(Price: $36)
Related Studies:
Peripheral endocannabinoid system dysregulation in first-episode psychosis.
Published via Neuropsychopharmacology
A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.
Published via Current Pharmaceutical Design
Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
Published via Drug Testing and Analysis
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.
Published via Translational Psychiatry
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Published via Brazilian Journal of Medical and Biological Research